BiotechTube
Home/Kinea Bio/Martin K. (Casey) Childers, DO, PhD
MK

Martin K. (Casey) Childers, DO, PhD

Chief Executive Officer

Kinea Bio

Therapeutic Areas

Neuromuscular Diseases

Kinea Bio Pipeline

DrugIndicationPhase
DMD Gene TherapyDuchenne Muscular DystrophyPre-clinical
Dysferlinopathy Gene TherapyDysferlinopathy (LGMD2B/LGMDR2)Pre-clinical
DM1 TherapyMyotonic Dystrophy Type 1Research

Leadership Team at Kinea Bio

JC
Jeffrey Chamberlain, PhD
Co-founder, Chief Scientific Advisor
SW
Seung Wook Oh, PhD
Chief Operating Officer
MC
Michael Cho, JD
Chief Financial Officer, Chief Strategy Officer, General Counsel
View full Kinea Bio profile